Vor Biopharma

VOR BIOPHARMA INC

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

pharmaceutical ARDX Ardelyx

News

Movers

Vor shares are higher lower on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing.

What&#39;s Going On With Vor Biopharma Shares Friday?

oracle shutter

Pre-Market Outlook

Markets

Trading Ideas

AMZN

ASNS

CNET

CNTM

EGIO

IONS

NUVB

ORCL

PSIG

QNRX

RBRK

SGLY

SLXN

SMTK

TVGN

VRDN

WENA

WHLR

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

Health Care

General

Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.

What&#39;s Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Vor Biopharma Inc

Virgin Orbit Holdings Inc

Virgin Orbit Holdings Inc Warrants (29/12/2026)

Vornado Realty Trust

VORNADO RLTY TR 6.50 A PR by Vornado Realty Trust

Vornado Realty Trust 5.25% Series M Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share, no par value per share

Vornado Realty Trust 5.25% Series N Cumulative Redeemable Preferred Shares of Beneficial Interest, liquidation preference $25.00 per share

Vornado Realty Trust 4.45% Series O Cumulative Redeemable Preferred Shares, Liquidation Preference $25.00 Per Share

Vortex Brands Co

VORTEX ENERGY CORP by Vortex Energy Corp.

Vortex Energy Corp

Vortex Metals Inc

Press Releases

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

Management

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Earnings

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

Analyst Ratings

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Financing

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

PRTC

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Atossa Therapeutics

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Coherus BioSciences

Caribou Biosciences

EXoZymes

Fate Therapeutics

Genelux

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Macrogenics

OncoCyte

Renovaro

Regulus Therapeutics

Senti Biosciences

Vigil Neuroscience

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Exicure

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Oppenheimer

Stifel

HC Wainwright & Co.

JMP Securities

Baird

Comments

Vor Biopharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga